Last updated: November 11, 2026
IMG-7289, now known as bomedemstat, is an investigational oral lysine-specific demethylase 1 (LSD1/KDM1A) inhibitor developed by Imago BioSciences and acquired by Merck in 2023 for approximately $1.35 billion. The program is focused on myeloproliferative neoplasms, particularly myelofibrosis (MF) and essential thrombocythemia (ET). Through mid-2024, bomedemstat remained in clinical development and had no FDA approval, commercial sales, or Orange Book listing. Its commercial value depends on whether it can show disease-modifying activity or a meaningful benefit over JAK inhibitors in MF and cytoreductive therapy in ET.
What is IMG-7289 and how does bomedemstat work?
Bomedemstat is an oral, irreversible inhibitor of LSD1, an epigenetic enzyme involved in hematopoietic stem-cell differentiation and abnormal megakaryocyte activity. The drug is designed to reduce pathological platelet production, modulate inflammatory signaling, and potentially affect the malignant stem-cell compartment associated with myeloproliferative neoplasms.
The principal development rationale is different from that of JAK inhibitors:
| Attribute |
Bomedemstat |
Ruxolitinib and other JAK inhibitors |
| Primary target |
LSD1/KDM1A |
JAK1/JAK2 or JAK2 |
| Route |
Oral |
Oral |
| Core development areas |
MF and ET |
MF, polycythemia vera and related MPNs |
| Intended clinical value |
Platelet control, symptom reduction, spleen control and possible disease modification |
Spleen and symptom control |
| Development status |
Investigational |
Approved drug class |
| FDA approval |
None |
Established for several MPN indications |
The drug’s differentiation strategy is strongest in ET, where long-term platelet control and reduction of thrombotic risk are important. In MF, the commercial bar is higher because approved JAK inhibitors already provide a standard treatment option.
What is the current clinical development status of IMG-7289?
Bomedemstat has been evaluated in clinical studies involving ET, MF and other hematologic malignancies. The principal focus shifted toward MPNs after early clinical activity supported continued development.
Essential thrombocythemia
In ET, bomedemstat has been studied in patients who were resistant or intolerant to available cytoreductive therapies. Public company disclosures described reductions in platelet counts and improvements in disease-related measures in a substantial proportion of treated patients.
The ET opportunity is commercially relevant because many patients require chronic platelet-lowering treatment, while existing options can be limited by intolerance, inadequate response, leukemic transformation concerns, or contraindications. Hydroxyurea remains widely used, but an oral targeted therapy with durable disease control could support premium pricing if it demonstrates a favorable safety profile.
Key development objectives in ET include:
- Durable platelet control.
- Reduction in thrombotic events.
- Reduction in disease-related symptoms.
- Lower treatment discontinuation rates.
- Utility in patients who fail or cannot tolerate hydroxyurea, interferon or anagrelide.
- Evidence of reduction in mutant allele burden or other disease-modifying activity.
Myelofibrosis
In MF, bomedemstat has been evaluated in patients with relapsed or refractory disease and in earlier-line settings. The program has sought to establish activity against splenomegaly, constitutional symptoms, anemia and abnormal megakaryocyte biology.
MF represents the larger strategic opportunity but also the more difficult clinical indication. A treatment competing against ruxolitinib, fedratinib, pacritinib and momelotinib must demonstrate a clear benefit in at least one commercially important segment. Potential positioning includes:
- Patients with inadequate response to a JAK inhibitor.
- Patients with anemia or thrombocytopenia limiting JAK-inhibitor use.
- Combination treatment with a JAK inhibitor.
- Frontline therapy if spleen and symptom data are competitive.
- Patients seeking a disease-modifying or stem-cell-directed treatment.
The key endpoint risk is that biologic activity may not translate into the regulatory endpoints required for approval. Spleen volume reduction, symptom response, transfusion independence and overall survival remain critical measures in MF development.
FDA regulatory status
As of mid-2024, bomedemstat was an investigational drug and had not received FDA approval. The program had received FDA Fast Track designation for MF, according to company disclosures. Fast Track designation can facilitate interaction with the FDA and rolling review of portions of an application, but it does not establish efficacy or guarantee accelerated approval.
No public information indicated that bomedemstat had received Breakthrough Therapy designation, Regenerative Medicine Advanced Therapy designation, or Priority Review.
When could IMG-7289 lose exclusivity?
IMG-7289 has not yet received an FDA approval date, so its regulatory exclusivity period has not started. If approved as a new chemical entity, it could receive five years of U.S. regulatory exclusivity under the Hatch-Waxman framework. Orphan-drug exclusivity could provide seven years for a qualifying indication, subject to the applicable statutory requirements.
Patent protection is separate from regulatory exclusivity. Merck inherited Imago’s patent estate covering LSD1 inhibitors, pharmaceutical compositions, treatment methods and potentially specific salts, formulations and manufacturing processes. Public commercial materials do not establish a single definitive loss-of-exclusivity date for bomedemstat. The relevant date will depend on:
- The patent claims covering the final commercial molecule.
- Patent-term adjustment.
- Any patent-term extension obtained after FDA approval.
- The scope of formulation and method-of-use claims.
- Whether later-filed continuation patents remain enforceable.
- The approved indications and the availability of skinny-label generic products.
Because the molecule is still investigational, it has no Orange Book patent listings. Any future Orange Book listing would depend on FDA approval and Merck’s submission of eligible patents.
What patents protect bomedemstat?
The inherited patent estate is expected to include several protection layers rather than a single composition-of-matter patent. The commercially relevant categories are:
| Patent category |
Potential protection |
Commercial significance |
| Composition of matter |
Bomedemstat molecule and related chemical genus |
Usually the strongest protection |
| Salts and solid forms |
Crystalline forms, salts and polymorphs |
Can protect manufacturing and product consistency |
| Pharmaceutical composition |
Oral tablets, excipients and dosage combinations |
May delay formulation substitution |
| Method of treatment |
Use in MF, ET or other hematologic diseases |
Can support label-specific enforcement |
| Combination therapy |
Use with JAK inhibitors or other MPN agents |
Relevant to combination regimens |
| Manufacturing |
Synthetic routes and intermediates |
Raises process-replication barriers |
The strength of the estate cannot be rated from the acquisition announcement alone. A definitive strength assessment requires claim-chart review, prosecution history, terminal-disclaimer analysis, patent-term calculations and assessment of invalidity risks under written-description, enablement, obviousness and anticipation standards.
What is the Orange Book status of IMG-7289?
Bomedemstat is not listed in the FDA Orange Book because it is not an approved drug. Consequently:
- No Orange Book-listed patents are currently available for a Paragraph IV challenge.
- No ANDA applicant can currently file a conventional Paragraph IV certification against bomedemstat.
- No approved-label method-of-use protection is yet enforceable through the Hatch-Waxman listing process.
- Future generic entry would depend on FDA approval, patent listings and the timing of any ANDA filing.
A biosimilar pathway is not relevant because bomedemstat is a small-molecule drug, not a biologic.
Which companies are challenging IMG-7289?
No public Paragraph IV litigation or ANDA challenge was identified for bomedemstat through mid-2024. The absence of challenges is expected for an unapproved small molecule with no Orange Book listing.
The competitive pressure comes from marketed MPN therapies and pipeline agents rather than generic litigation. Important competitors include:
- Incyte’s ruxolitinib.
- Bristol Myers Squibb’s fedratinib.
- CTI Biopharma’s pacritinib, acquired by Sobi.
- GlaxoSmithKline’s momelotinib.
- Roivant and other developers pursuing MPN-targeted therapies.
- Interferon-based products and established cytoreductive treatments in ET.
How does bomedemstat compare with competing MPN drugs?
| Drug |
Company |
Main MPN use |
Competitive position |
| Ruxolitinib |
Incyte |
MF and polycythemia vera |
Established first-line JAK inhibitor |
| Fedratinib |
Bristol Myers Squibb |
MF |
JAK2 inhibitor with activity after ruxolitinib |
| Pacritinib |
Sobi |
MF with severe thrombocytopenia |
Differentiated by platelet-count profile |
| Momelotinib |
GSK |
MF, particularly anemia |
Differentiated by anemia and transfusion benefits |
| Hydroxyurea |
Multiple manufacturers |
ET and polycythemia vera |
Low-cost, established cytoreductive therapy |
| Ropeginterferon alfa-2b |
PharmaEssentia |
Polycythemia vera |
Long-acting interferon option |
| Bomedemstat |
Merck |
Investigational MF and ET |
Potential LSD1-based differentiation |
Bomedemstat must demonstrate a clinically meaningful advantage rather than only pharmacodynamic activity. In ET, the most credible commercial differentiation is durable platelet control with tolerable long-term administration. In MF, differentiation may require a combination of spleen response, symptom control, anemia performance and activity after JAK-inhibitor failure.
What is the market projection for IMG-7289?
A reasonable commercial forecast is scenario-based because bomedemstat has no approved label, price or confirmed pivotal efficacy result.
Addressable population
The U.S. market includes tens of thousands of patients with MF and a larger population with ET. The treatable market is smaller than total prevalence because some patients are monitored without active cytoreduction, receive transplant-based care, or are medically unsuitable for chronic therapy.
The most commercially relevant populations are:
- JAK-inhibitor-naive MF patients.
- MF patients with inadequate response or intolerance to a JAK inhibitor.
- ET patients with hydroxyurea resistance or intolerance.
- Patients requiring chronic platelet control but seeking alternatives to existing therapy.
- Combination-treatment populations if bomedemstat shows additive benefit.
Revenue scenarios
| Scenario |
Commercial assumption |
Estimated peak annual sales |
| Low |
Approval in one narrower, later-line indication; limited adoption |
$200 million-$500 million |
| Base |
Approval in ET and a later-line MF population; premium oral pricing |
$700 million-$1.3 billion |
| High |
Broad MF and ET labels, strong combination use and disease-modifying evidence |
$1.5 billion-$2.5 billion |
The base case assumes approximately 5,000 to 10,000 treated patients across the U.S. and major European markets, with annual net revenue per patient in the approximate range of $100,000 to $150,000. The high case requires broader uptake, durable clinical benefit and payer acceptance of combination treatment.
The acquisition price paid by Merck implied expectations of multibillion-dollar potential across indications, not merely a single MF label. The program’s valuation depends on expansion beyond a refractory population.
What generic launch risks exist for bomedemstat?
Generic entry risk is low before approval and potentially material after loss of composition-of-matter protection. The primary risks are:
- Paragraph IV challenges against composition or method patents.
- Invalidity attacks on continuation patents.
- Design-around products using different salts or formulations.
- Skinny-label entry for an unprotected indication.
- Patent-term limitations caused by early filing dates.
- Competition from lower-cost cytoreductive therapies.
- Payer restrictions if clinical differentiation is modest.
The strongest protection would ordinarily come from a valid composition-of-matter patent extending into the commercial period. Formulation and method-of-use patents can add value, but they are more vulnerable to label design-around and narrower claim scope.
What licensing or transaction affects IMG-7289?
Merck acquired Imago BioSciences in an all-cash transaction valued at approximately $1.35 billion, or $36 per share, in January 2023. The transaction transferred control of bomedemstat and Imago’s related intellectual property and clinical programs to Merck. It was an acquisition rather than a conventional out-licensing agreement.
The transaction gave Merck an internally controlled development program in MPNs while adding a mechanism distinct from its existing commercial oncology portfolio. No separate public licensing deal has been identified as the principal commercial transaction for bomedemstat.
Key Takeaways
- IMG-7289 is bomedemstat, an investigational oral LSD1 inhibitor owned by Merck after its acquisition of Imago BioSciences.
- Its lead indications are MF and ET.
- The drug had no FDA approval, Orange Book listing or Paragraph IV litigation through mid-2024.
- ET is the clearest differentiation opportunity because chronic platelet control remains clinically important.
- MF is the larger opportunity but has stronger competition and higher clinical requirements.
- A realistic peak-sales range is approximately $700 million to $1.3 billion in a base case, with upside above $1.5 billion if the drug achieves broad MF and ET adoption.
- Patent value depends on the enforceability and duration of the inherited composition, formulation, treatment-method and manufacturing claims.
- Merck’s $1.35 billion acquisition price indicates a strategic expectation of value across more than one MPN indication.
FAQs
Is IMG-7289 the same drug as bomedemstat?
Yes. IMG-7289 is the development code for bomedemstat, an oral LSD1/KDM1A inhibitor.
Is bomedemstat approved by the FDA?
No. Bomedemstat remained investigational through mid-2024 and was not listed in the FDA Orange Book.
Can a generic company file a Paragraph IV challenge against IMG-7289?
Not before FDA approval and Orange Book patent listing. No public Paragraph IV challenge was identified through mid-2024.
Does bomedemstat have biosimilar competition risk?
No. Bomedemstat is a small-molecule drug, so future competition would arise through the ANDA generic pathway rather than the biosimilar pathway.
What would most improve the commercial outlook for bomedemstat?
The strongest value catalysts would be approval in both ET and MF, durable benefit after JAK-inhibitor failure, meaningful anemia or transfusion benefits, and clinical evidence supporting combination use with an approved JAK inhibitor.
References
-
Merck & Co., Inc. (2023). Merck to acquire Imago BioSciences, Inc., expanding its oncology pipeline with a novel investigational therapy. Merck press release.
-
Imago BioSciences, Inc. (2022). Imago announces FDA Fast Track designation for bomedemstat in myelofibrosis. Company press release.
-
U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.
-
ClinicalTrials.gov. (2024). Studies evaluating bomedemstat (IMG-7289) in myelofibrosis and essential thrombocythemia. U.S. National Library of Medicine.
-
Merck & Co., Inc. (2024). Annual report for the fiscal year ended December 31, 2023. Merck & Co., Inc.
